Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5,6-methylenedioxy-2-aminoindane
- Development stage
- Preclinical
- Lead developer
- Purdue University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
5,6-methylenedioxy-2-aminoindane (MDAI) is a synthetic entactogen and research compound belonging to the 2-aminoindane family. Structurally related to 3,4-methylenedioxymethamphetamine (MDMA), it was originally synthesized in the 1990s by David Nichols' research group at Purdue University to investigate non-neurotoxic alternatives to MDMA. MDAI acts as a selective serotonin and norepinephrine releasing agent (SNRA), with significantly lower potency for dopamine release compared to MDMA, a profile intended to reduce dopaminergic neurotoxicity. Although it has been investigated in academic settings for its potential as a non-neurotoxic alternative to MDMA in psychotherapy, it has never undergone formal clinical development by a pharmaceutical company. Instead, it emerged on the recreational drug market around 2010 as a 'legal high' or new psychoactive substance (NPS).
- Other names
- MDAI6,7-dihydro-5H-cyclopenta[f][1,3]benzodioxol-6-amine
02
Targets
SERT (Sodium-dependent serotonin transporter)ADRA2A (α2A)NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)
Beyond the preview
Go deeper on 5,6-methylenedioxy-2-aminoindane.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5,6-methylenedioxy-2-aminoindane.